Diabetes and it’s related outcomes are expected to be a significant problem worldwide, with a projected 1 in 2 diabetic patients being undiagnosed by 2030.
The potential to vastly enhance chronic illness management such as Type 2 Diabetes Mellitus (T2DM) is still largely untapped.
By monitoring blood glucose levels, RE.DOCTOR provides the ability to pre-emptively identify individuals with pre-diabetes and potentially allow diabetics to dynamically manage their treatment for better blood glucose control.
RE.DOCTOR leverages the latest technological advancement in signal processing, PPG technologies, and artificial intelligence (AI) to assess the risk of impaired glucose regulation.
Approximately 537 million adults (20-79 years) are living with diabetes.
While there are a number of factors that influence the development of type 2 diabetes, it is evident that the most influential are lifestyle behaviours commonly associated with urbanization.
These include consumption of unhealthy foods and inactive lifestyles with sedentary behaviour. Studies from different parts of the world have established that lifestyle modification with physical activity and/or healthy diet can delay or prevent the onset of type 2 diabetes.
Modern lifestyles are characterised by physical inactivity and long sedentary periods. Community-based interventions can reach individuals and families through campaigns, education, social marketing and encourage physical activity both inside and outside school and the workplace. IDF recommends physical activity at least between three to five days a week, for a minimum of 30-45 minutes.
Taking a life course perspective is essential for preventing type 2 diabetes and its complications. Early in life, when eating and physical activity habits are established and when the long-term regulation of energy balance may be programmed, there is an especially critical window to prevent the development of overweight and reduce the risk of type 2 diabetes. Healthy lifestyles can improve health outcomes at later stages of life as well.
In the ever-evolving healthcare landscape, pharmaceutical companies are continuously seeking innovative ways to enhance their treatment offerings. In this pursuit, digital therapeutics (DTx) have emerged as a transformative force, offering a personalized and data-driven approach to complement traditional pharmacotherapy. Leading the charge in this realm is RE.DOCTOR, a pioneer in DTx solutions, empowering pharmaceutical companies to seamlessly integrate DTx into their treatment strategies.
RE.DOCTOR’s comprehensive DTx platform seamlessly integrates with existing pharmaceutical products, providing a holistic approach to patient care. This integration enables seamless data exchange between DTx and pharmacotherapy, fostering a deeper understanding of patient responses and treatment outcomes. By leveraging RE.DOCTOR’s DTx solutions, pharmaceutical companies can:
The integration of RE.DOCTOR’s DTx solutions into pharmaceutical treatment plans offers a multitude of benefits for patients. DTx can provide:
Through its collaboration with pharmaceutical companies, RE.DOCTOR is revolutionizing the healthcare industry, paving the way for a future where DTx seamlessly complements pharmacotherapy to deliver personalized, data-driven, and patient-centric care.
North America: +1-307-278-9811
Our solutions are not a replacement for a healthcare professional and our solution does not diagnose, prevent, provide any treatment for any form of illness or disease.